Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients

Eli Lilly and Company announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound Self Pay Journey Program (Zepbound Self Pay Journey Program lowers the price of the 7.5 mg and 10 mg vials only on first fill and when prescriptions are refilled within 45 days of their previous delivery. 7.5 mg and 10 mg vials are priced at $599 and $699, respectively, if refilled outside of the 45-day window). Lilly also reduced the price of the 2.5 mg and 5 mg vials. These new offerings are available exclusively through LillyDirect Self Pay Pharmacy Solutions, which enables a transparent price by removing third-party supply chain entities and allowing patients to access savings directly outside of insurance.

Self-pay patients with obesity now have additional Zepbound vial options, including 2.5 mg, 5 mg, 7.5 mg and 10 mg doses. In addition to expanding the doses available, Lilly is taking steps to make Zepbound vials more affordable, including: i) Lowering the price of the 2.5 mg dose to $349 per month. ii) Lowering the price of the 5 mg dose to $499 per month.

Zepbound is also available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg per 0.5 mL doses in a single-dose pen (autoinjector). The recommended maintenance dosages are 5 mg, 10 mg or 15 mg injected subcutaneously once weekly. Those starting on Zepbound will take Zepbound 2.5 mg for four weeks before increasing their dosage to 5 mg.